NovaBridge Biosciences

CIK 0001778016 · NBP Nasdaq

SIC
2834 · Pharmaceutical Preparations
Status
Public
Filer
Non-accelerated filer
Incorporated
Cayman Islands
FY End
Dec 31

About NovaBridge Biosciences

NovaBridge Biosciences is a non-accelerated filer incorporated in Cayman Islands, classified under SIC 2834 (Pharmaceutical Preparations). It files with the SEC under Central Index Key 0001778016, and its shares are listed as NBP on Nasdaq. Its most recent filing on EDGAR is a SCHEDULE 13D/A, filed November 5, 2026. 47 institutional investment managers reported holding its shares on Form 13F for Q3 2026, against 49 in Q2 2026. Its officers, directors and 10% owners have filed 16 Form 4 reports since 2026. 3 investors report a stake of 5% or more on Schedule 13D or 13G.

Across SEC filings

Institutional holders · 13F

Q3 2026
47 managers reported a position for Q3 2026 -2 vs Q2 2026
Largest Q3 2026 Form 13F holders of NovaBridge Biosciences by reported value
Largest holders Reported value
HHLR ADVISORS LTD $8.2M
MORGAN STANLEY $4.7M
AIHC Capital Management Ltd $3.9M
CITADEL ADVISORS LLC $1.9M
Candriam S C A $1.6M

5%+ holders · 13D/G

3 filers
Schedule 13D and 13G filers reporting a stake of 5% or more
Filer % of class Filed
HHLR ADVISORS LTD 13D 4.9% 2026-11-06
CBC Investment I-Mab Limited 13D 11.5% 2026-02-03
Everest Medicines Limited 13D 16.1% 2025-08-05

Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.

Insider trades · Form 4

+$423K net open-market insider transactions, last 12 months 1 filing with purchases ($577K), 7 filings with sales ($154K)

Latest filings

Securities

Securities issued by this company
CUSIP Security Type
44975P103 NBP NOVABRIDGE BIOSCIENCES Adr

Latest SEC filings

All filings →
Latest SEC filings by NovaBridge Biosciences
Form Description Filed
SCHEDULE 13D/A SCHEDULE 13D/A 2026-11-05
3 Initial Ownership 2026-11-02
6-K Foreign Current Report 2026-10-28
6-K Foreign Current Report 2026-10-26
6-K Foreign Current Report 2026-10-23
4 Insider Transaction · Ian Ying Woo 2026-10-19
6-K Foreign Current Report 2026-10-13
4 Insider Transaction · Phillip Andrew Dennis 2026-09-21
144 144 2026-09-18
4 Insider Transaction · Sean Wuxiong Cao 2026-09-11
Loading ownership data...
Loading insider trading data...
Loading financials...

Quality is a Plus feature

See why the score is what it is — the score history and the full test-by-test breakdown behind the composite.

Valuation is a Premium feature

What this company is worth versus its price — fair value at today's bond rate, margin of safety, and the Graham Number against the institutional consensus price.

Loading SEC filings...